Skip to main content
. 2021 Apr 22;7(5):324. doi: 10.3390/jof7050324

Figure 1.

Figure 1

Study design and patient population. iV: initial visit, V.1mo, V.2mo, V.3mo, V.6mo: visits at 1, 2, 3, and 6 months. P: placebo; F: fluconazole; NR: no recurrence; R: recurrence. ⨀ Mouth swabs and stool sampling: isolation, identification, and quantification of yeasts. Serum sampling: (♦) calprotectin levels; (✜) Crohn’s disease (CD) anti-glycan antibodies (ASCA, anti-chitobioside (ACCA), anti-laminaribioside (ALCA), and AMCA); (■) anti-C. albicans antibodies (CalbManAb, CalbProtAb); (✖) innate immunity lectins: galectin-3, mannose binding lectin.